Press Releases

Greenphire Launches New Clinical Trial Budget Build and Negotiation Solution, EnvisiX

Greenphire, the global leader in financial lifecycle management for clinical trials, announced the launch of EnvisiX to address the budgeting challenges experienced by global sponsors and CROs during study start-up. The new budget development solution streamlines trial initiation for...

AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ for the Treatment of Adults with Active Psoriatic Arthritis

AbbVie , a research-based global biopharmaceutical company, announced that it has submitted applications for a new indication to the U.S. FDA and European Medicines Agency (EMA) for RINVOQ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor,...

Daiichi Sankyo and Syneos Health Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline

Daiichi Sankyo, Inc. announced that it has entered into a strategic agreement with Syneos Health The companies are coming together to form a coalition to accomplish their shared goal of bringing promising cancer therapies to patients as safely, effectively...

Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

Junshi Biosciences , a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel therapies, and Merck, a world leading science and technology company, announced their collaboration on a clinical trial program designed to investigate the efficacy and...

Lilly Begins World’s First Study of a Potential COVID-19 Antibody Treatment in Humans

Eli Lilly and Company announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly...

Honeywell Expedites Development and Production of Vital Vaccines and Medical Therapies with Fast Track Automation

Honeywell announced Fast Track Automation, a combination of proprietary technology innovations for the life sciences industry that enables vital vaccines, treatments and therapies to move from regulatory approval to full production in as little as two months depending on...

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS

Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA)...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read